RAPPORT THERAPEUTICS, INC. COMMON STOCK
NASDAQ: RAPP (Rapport Therapeutics, Inc.)
Kemas kini terakhir: 13 jam lalu12.04
0.24 (2.03%)
Penutupan Terdahulu | 11.80 |
Buka | 12.06 |
Jumlah Dagangan | 56,236 |
Purata Dagangan (3B) | 175,452 |
Modal Pasaran | 439,432,320 |
Harga / Buku (P/B) | 1.54 |
Julat 52 Minggu | |
Tarikh Pendapatan | 7 Aug 2025 |
EPS Cair (TTM) | -3.82 |
Jumlah Hutang/Ekuiti (D/E MRQ) | 2.74% |
Nisbah Semasa (MRQ) | 31.01 |
Aliran Tunai Operasi (OCF TTM) | -67.45 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -47.00 M |
Pulangan Atas Aset (ROA TTM) | -22.89% |
Pulangan Atas Ekuiti (ROE TTM) | -33.14% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Menurun | Menurun |
Biotechnology (Global) | Menurun | Menurun | |
Stok | Rapport Therapeutics, Inc. | Menurun | - |
AISkor Stockmoo
Konsensus Penganalisis | -0.5 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -2.0 |
Purata Bergerak Teknikal | -1.0 |
Osilator Teknikal | 2.0 |
Purata | -0.38 |
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function. |
|
Sektor | Healthcare |
Industri | Biotechnology |
% Dimiliki oleh Orang Dalam | 6.40% |
% Dimiliki oleh Institusi | 105.23% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
Trv Gp V, Llc | 31 Mar 2025 | 7,135,233 |
Cormorant Asset Management, Lp | 31 Mar 2025 | 2,940,921 |
Capital International Investors | 31 Mar 2025 | 2,602,529 |
Johnson & Johnson | 31 Mar 2025 | 2,498,051 |
Sofinnova Investments, Inc. | 31 Mar 2025 | 1,995,594 |
T. Rowe Price Investment Management, Inc. | 31 Mar 2025 | 1,551,925 |
Goldman Sachs Group Inc | 31 Mar 2025 | 1,244,310 |
Trv Gp Vi, Llc | 31 Mar 2025 | 969,218 |
Julat 52 Minggu | ||
Median | 28.00 (132.56%) | |
Jumlah | 1 Beli |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
JMP Securities | 08 Apr 2025 | 28.00 (132.56%) | Beli | 8.72 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
02 Jun 2025 | Pengumuman | Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates |
21 May 2025 | Pengumuman | Rapport Therapeutics to Host 2025 Investor and Analyst Day |
08 May 2025 | Pengumuman | Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update |
22 Apr 2025 | Pengumuman | Rapport Therapeutics to Participate in Upcoming Investor Conferences |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |